Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, Dolegowska B (2019) FGF19 subfamily members: FGF19 and FGF21. J Physiol Biochem 75(2):229–240

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erben RG (2018) Physiological actions of fibroblast growth factor-23. Front Endocrinol 9:267

Article  Google Scholar 

Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM et al (2011) FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 6(3):e17868

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spann RA, Morrison CD, den Hartigh LJ (2021) The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol 12:802541

Article  Google Scholar 

Barutcuoglu B et al (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41(4):390–396

CAS  PubMed  Google Scholar 

Ryan PM et al (2020) Effect of bariatric surgery on circulating FGF-19: a systematic review and meta-analysis. Obes Rev 21(8):e13038

Article  PubMed  Google Scholar 

Yan J, Nie Y, Cao J, Luo M, Yan M, Chen Z, He B (2021) The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med 8:655575

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin L, Yang R, Geng L, Xu A (2023) Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications. Annu Rev Pharmacol Toxicol 63:359–382

Article  CAS  PubMed  Google Scholar 

Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP et al (2023) Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 389(11):998–1008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP et al (2021) Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 160(1):219–231

Article  CAS  PubMed  Google Scholar 

Su N, Jin M, Chen L (2014) Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res 2:14003

Article  PubMed  PubMed Central  Google Scholar 

Chen H, Li J, Zhang D, Zhou X, Xie J (2021) Role of the fibroblast growth factor 19 in the skeletal system. Life Sci 265:118804

Article  CAS  PubMed  Google Scholar 

Guo A, Li K, Tian HC, Tao BL, Xiao Q, Jiang DM (2022) FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation. Biomed Pharmacother 146:112524

Article  CAS  PubMed  Google Scholar 

Zhao YX, Song YW, Zhang L, Zheng FJ, Wang XM, Zhuang XH et al (2020) Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics 75:e1486

Article  PubMed  PubMed Central  Google Scholar 

Tang Y, Zhang M (2023) Fibroblast growth factor 21 and bone homeostasis. Biomed J 46(4):100548

Article  CAS  PubMed  Google Scholar 

Lee P, Linderman J, Smith S, Brychta RJ, Perron R, Idelson C et al (2013) Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos Int 24(12):3053–3057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi HS, Lee HA, Kim SW, Cho EH (2018) Association between serum fibroblast growth factor 21 levels and bone mineral density in postmenopausal women. Endocrinol Metab 33(2):273–277

Article  CAS  Google Scholar 

Lui DTW, Lee CH, Chau VWK, Fong CHY, Yeung KMY, Lam JKY et al (2021) Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance. J Endocrinol Invest 44(3):523–530

Article  CAS  PubMed  Google Scholar 

Moore AE, Kim E, Dulnoan D, Dolan AL, Voong K, Ahmad I et al (2020) Serum vitamin K(1) (phylloquinone) is associated with fracture risk and hip strength in post-menopausal osteoporosis: a cross-sectional study. Bone 141:115630

Article  CAS  PubMed  Google Scholar 

Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5(2):49–55 (Epub 2007/05/25)

Article  PubMed  Google Scholar 

Henriksson E, Andersen B (2020) FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front Endocrinol 11:601349

Article  Google Scholar 

Hao Y, Zhou J, Zhou M, Ma X, Lu Z, Gao M et al (2013) Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals. PLoS ONE 8(8):e72345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu X, Xia Y, Jia J, Yuan G (2022) The role of fibroblast growth factor 19 subfamily in different populations suffering from osteoporosis. Front Endocrinol 13:830022

Article  Google Scholar 

Yamamoto S, Koyama D, Igarashi R, Maki T, Mizuno H, Furukawa Y, Kuro OM (2020) Serum endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease and various metabolic dysfunctions in aged patients. Intern Med 59(3):345–355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X et al (2017) Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE 12(6):e0178580

Article  PubMed  PubMed Central  Google Scholar 

LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R et al (2010) Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density? Osteoporos Int 21(6):919–929 (Epub 2009/09/17)

Article  CAS  PubMed  Google Scholar 

Fazeli PK, Faje AT, Cross EJ, Lee H, Rosen CJ, Bouxsein ML, Klibanski A (2015) Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa. Bone 77:6–11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gawlik K, Milewicz T, Pawlica-Gosiewska D, Trznadel-Morawska I, Solnica B (2023) Fibroblast growth factor 21 in gestational diabetes mellitus and type 2 diabetes mellitus. J Diabetes Res 2023:4024877

Article  PubMed  PubMed Central  Google Scholar 

Sundararaghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA (2017) Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 9(3):67–74

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109(8):3143–3148

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31(5):845–851